Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making compounded versions of the weight-loss medication ...
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
腾讯网3 天
FDA“三思“将礼来(LLY.US)减肥神药移除短缺名单，Hims & Hers Health(HIMS.US ...
智通财经APP获悉，在美国食品药品监督管理局(FDA)决定将礼来公司(LLY.US)的替西帕肽(Tirzepatide)从药品短缺清单中移除后，一起针对此次除名举措的诉讼引发了Hims & Hers Health(HIMS.US)周一交易上涨，收涨9 ...
Health on MSN2 天
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
腾讯网6 天
美国肥胖群体的福音：FDA考虑允许复配版礼来(LLY.US)减肥药
智通财经APP获悉，美国食品和药物管理局(FDA)在周五同意重新考虑上个月所作出的决定，即禁止私人的药物配制商销售他们自己复合制作版本的礼来公司(LLY.US)减肥以及治疗糖尿病药物。该机构在一份法庭文件中表示，现在将考虑允许复配药房和药物基础设施继 ...
FiercePharma4 天
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
BofA上调Hims and Hers目标价，因FDA药品更新
BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...
WKBW3 天
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
FDA将礼来GLP-1减肥药从短缺名单中删除，配药团体提起诉讼
美国 FDA 于上周宣布胰高血糖素样肽1（GLP-1）药物替尔泊肽（tirzepatide）注射液的短缺问题已得到解决，并提醒配药商配制已获得 FDA 批准的药品受到法律限制。根据配药相关法律规定，如果已批准的药品在 FDA ...
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
Truist维持对HIMS的持有评级，FDA审查进展引关注
Truist Securities维持对Hims & Hers Health, Inc. (NYSE:HIMS)的持有评级，目标价保持在$23.00。该公司分析师引用了美国食品和药物管理局(FDA)最近决定重新审视Tirzepatide短缺问题，并继续授权复合药房生产其复合版本，认为这对公司前景有利。 这一决定对Hims & Hers的复合GLP-1产品尤为相关，该产品使用的Semaglutide ...